Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (HK:8189)
:8189
Top Page
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H
(8189)
Select Model
Select Model
Rating:40Underperform
Price Target:
HK$0.33
▼(-18.00% Downside)
Action:UpgradedDate:01/29/26
The score is primarily constrained by very weak financial performance: ongoing losses, heavy leverage, and persistently negative operating/free cash flow indicate elevated financial risk. Technicals provide only modest support with short-term strength but a still-weak longer-term trend. Valuation is also unfavorable/unclear due to a negative P/E driven by losses and no dividend yield data.
Positive Factors
Diverse Revenue Streams
The company's diverse revenue streams, including medical devices, biopharmaceuticals, and partnerships, provide a robust foundation for long-term growth and resilience against market fluctuations.
Negative Factors
High Leverage
The significant increase in leverage indicates a heavy reliance on debt financing, which poses financial risks and limits the company's flexibility in managing economic downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Diverse Revenue Streams
The company's diverse revenue streams, including medical devices, biopharmaceuticals, and partnerships, provide a robust foundation for long-term growth and resilience against market fluctuations.
Read all positive factors
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$618.98M
Dividend YieldN/A
Average Volume (3M)1.41M
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue Growth-5.79%
EPS Growth-129.73%
CountryHK
Employees260
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,436,400,000
10 Day Avg. Volume824,500
30 Day Avg. Volume1,413,333
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)24.48
Price to Sales (P/S)1.41
P/FCF Ratio-18.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Tianjin TEDA Biomedical Engineering Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of biological compound fertilizer products in the People's Republic of China. The company operates in ...
How the Company Makes Money
Tianjin TEDA Biomedical Engineering generates revenue through multiple streams including the sale of medical devices and biopharmaceutical products to hospitals, clinics, and healthcare providers. Additionally, the company may engage in research a...
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
35
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 226.41M | 385.48M | 398.00M | 403.73M | 476.38M | 369.36M |
| Gross Profit | 13.82M | 16.97M | 21.37M | 14.82M | 45.60M | 40.39M |
| EBITDA | -3.20M | -20.19M | 4.79M | -2.26M | -29.86M | -21.52M |
| Net Income | -6.43M | -27.80M | -20.16M | -27.45M | -42.26M | -48.00M |
Balance Sheet | ||||||
| Total Assets | 415.16M | 332.53M | 303.28M | 337.20M | 347.60M | 392.92M |
| Cash, Cash Equivalents and Short-Term Investments | 186.13M | 25.40M | 5.93M | 9.55M | 29.78M | 35.53M |
| Total Debt | 112.58M | 159.92M | 83.56M | 102.61M | 90.34M | 54.65M |
| Total Liabilities | 314.26M | 304.09M | 238.70M | 253.48M | 237.24M | 237.77M |
| Stockholders Equity | 96.62M | 22.15M | 49.95M | 70.11M | 100.78M | 143.04M |
Cash Flow | ||||||
| Free Cash Flow | -99.23M | -28.83M | -15.62M | -21.62M | -40.38M | 21.96M |
| Operating Cash Flow | -98.40M | -26.27M | -13.15M | -12.82M | -6.68M | 35.99M |
| Investing Cash Flow | 6.72M | -37.24M | -467.44K | -12.93M | -8.51M | -26.51M |
| Financing Cash Flow | 78.55M | 82.95M | 12.73M | 6.17M | 28.10M | -20.19M |
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Technical Analysis
Negative
0.40
Price Trends
0.31
Negative
0.32
Negative
0.38
Negative
Market Momentum
>-0.01
Positive
41.21
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8189, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.30, above the 50-day MA of 0.31, and above the 200-day MA of 0.38, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.21 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8189.
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$11.24B | 7.77 | 11.27% | 3.66% | -0.34% | 64.10% | |
71 Outperform | HK$14.09B | 10.97 | 9.60% | 3.23% | 0.82% | 2.99% | |
70 Outperform | HK$13.37B | 10.56 | 5.19% | 5.44% | -8.24% | -24.53% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
43 Neutral | HK$365.46M | -0.19 | -179.93% | ― | -22.72% | -212.73% | |
40 Underperform | HK$618.98M | -57.48 | -8.95% | ― | -5.79% | -129.73% |
* Basic Materials Sector Average
HK:8189
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H
0.29
-0.15
-34.09%
HK:3983
China BlueChemical
2.90
1.21
71.39%
HK:0297
Sinofert Holdings
1.60
0.51
46.79%
HK:1866
China XLX Fertiliser Ltd.
10.98
7.17
188.19%
HK:0827
Ko Yo Chemical (Group) Limited
0.05
0.02
67.74%
HK:0509
Century Sunshine Group Holdings Limited
0.17
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.